Player FM 앱으로 오프라인으로 전환하세요!
04_03 Metastatic Castrate Sensitive Prostate Cancer
Manage episode 399372794 series 3335024
1. The chemotherapy revolution in prostate cancer
2. Role of ARATs in earlier disease states
3. Triple therapy (chemotherapy, ADT, and ARAT)
4. Considerations for frailer patients with indolent disease
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041
2. Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/
3. Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1
4. Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3
5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4
6. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0
7. James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/
8. Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8
9. James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5
10. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0
11. Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\
12. James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5
13. Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174
14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720
15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 에피소드
04_03 Metastatic Castrate Sensitive Prostate Cancer
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 399372794 series 3335024
1. The chemotherapy revolution in prostate cancer
2. Role of ARATs in earlier disease states
3. Triple therapy (chemotherapy, ADT, and ARAT)
4. Considerations for frailer patients with indolent disease
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041
2. Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/
3. Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1
4. Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3
5. Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4
6. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0
7. James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/
8. Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8
9. James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5
10. Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0
11. Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\
12. James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5
13. Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174
14. Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720
15. Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.